| # | Concept | H-Index | Publications | Citations |
|---|---|---|---|---|
1 | Engineering | 11 | 40 | 2.1K |
2 | Management | 5 | 14 | 1.2K |
3 | Arts | 1 | 3 | 99 |
4 | Business | 1 | 1 | 11 |
5 | Health Sciences | 1 | 1 | 31 |
Revolution Medicines (United States)
×
255
Publications
39.1K
Citations
| Year | Citations | |
|---|---|---|
2018 | 407 | |
2024 | 268 | |
2012 | 206 | |
2024 | 150 | |
2022 | 136 | |
2011 | 126 | |
652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) Kathryn C. Arbour, Salman R. Punekar, Ignacio Garrido‐Laguna, Tumor BiologyMedicinePharmacologyPathologyPreliminary Clinical Activity | 2023 | 102 |
2018 | 96 | |
2020 | 95 | |
2018 | 75 |
Page 1
Page 1